Colby S. Shemesh
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 11
- CAR-T cell therapy research 7
- Pancreatic and Hepatic Oncology Research 5
- Peptidase Inhibition and Analysis 5
- Colorectal Cancer Treatments and Studies 4
- Immunology top 10%
- Biosimilars and Bioanalytical Methods 4
-
- RNA Interference and Gene Delivery 4
-
- Lymphoma Diagnosis and Treatment 5
- Co-authors
- Anand RotteSandhya GirishBenjamin WuJoy HsuPatrick TwomeyBen‐Quan ShenIraj HosseiniHailing Zhang
- Cited by
- OncologyImmunologyMolecular Biology
- Journals
- Journal of Clinical Oncology (3 papers)Cancer Research (2 papers)The Lancet Oncology (2 papers)
- Partner nations
- United StatesFranceSwitzerland
In The Last Decade
Colby S. Shemesh
33 papers receiving 878 citations
Hit Papers
Peers
Comparison fields: 5 of 78
- Oncology 373
- Immunology 268
- Molecular Biology 343
- Biomaterials 61
- Pulmonary and Respiratory Medicine 145
Countries citing papers authored by Colby S. Shemesh
This map shows the geographic impact of Colby S. Shemesh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colby S. Shemesh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colby S. Shemesh more than expected).
Fields of papers citing papers by Colby S. Shemesh
This network shows the impact of papers produced by Colby S. Shemesh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colby S. Shemesh. The network helps show where Colby S. Shemesh may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Colby S. Shemesh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, studybreakdown → | 2025 | 26 |
| 2 | 2024 | 12 | |
| 3 | 2023 | 9 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 37 | |
| 7 | 2023 | 5 | |
| 8 | 2022 | 6 | |
| 9 | 2021 | 4 | |
| 10 | 2020 | 6 | |
| 11 | 2020 | 11 | |
| 12 | 2020 | 13 | |
| 13 | 2020 | 6 | |
| 14 | 2020 | 188 | |
| 15 | 2019 | 105 | |
| 16 | 2019 | 36 | |
| 17 | 2017 | 27 | |
| 18 | 2016 | 46 | |
| 19 | 2014 | 57 | |
| 20 | 2014 | 51 |
About Colby S. Shemesh
Colby S. Shemesh is a scholar working on Oncology, Hepatology and Immunology, having authored 33 papers that have together received 899 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (7 papers), Pancreatic and Hepatic Oncology Research (5 papers), Peptidase Inhibition and Analysis (5 papers), Lymphoma Diagnosis and Treatment (5 papers), RNA Interference and Gene Delivery (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). The work is most often cited by research in Oncology (373 citations), Immunology (268 citations) and Molecular Biology (343 citations). Colby S. Shemesh has collaborated with scholars based in United States, France and Switzerland. Frequent co-authors include Anand Rotte, Sandhya Girish, Benjamin Wu, Joy Hsu, Patrick Twomey, Ben‐Quan Shen, Iraj Hosseini, Hailing Zhang, Hailing Zhang and Scott P. Henry. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.